We are live on
!
Find out more
KA
Kintegral Advisory Portfolio holdings
AUM
$1.06B
1-Year Est. Return
24.93%
This Fund
S&P 500
This Quarter
Est. Return
+10.75%
1 Year Est. Return
+24.93%
3 Year Est. Return
+94.38%
5 Year Est. Return
+128.14%
10 Year Est. Return
–
AUM
$550M
AUM Growth
+$47.8M
(+9.5%)
Cap. Flow
-$677K
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
28.86%
Holding
269
New
1
Increased
2
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$991K |
| 2 |
Truist Financial
TFC
|
+$326K |
| 3 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$45K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.72M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$320K |
| 3 |
3M
MMM
|
+$560 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.68% |
| 2 | Healthcare | 14.72% |
| 3 | Financials | 13.9% |
| 4 | Communication Services | 10.73% |
| 5 | Consumer Staples | 7.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Biogen
BIIB
$29.6B
| $2.15M | 0.39% |
7,260
| – | – |
|
77
Kimberly-Clark
KMB
$35.6B
| $2.15M | 0.39% |
15,481
| – | – |
|
78
Cardinal Health
CAH
$52.9B
| $2.13M | 0.39% |
41,756
| – | – |
|
79
State Street
STT
$50.6B
| $2.1M | 0.38% |
26,432
| – | – |
|
80
Citigroup
C
$221B
| $2.07M | 0.38% |
25,909
| – | – |
|
81
Mettler-Toledo International
MTD
$26.9B
| $2.02M | 0.37% |
2,546
| – | – |
|
82
Mondelez International
MDLZ
$77.1B
| $1.98M | 0.36% |
35,804
| – | – |
|
83
HP
HPQ
$22.4B
| $1.86M | 0.34% |
89,787
| – | – |
|
84
Automatic Data Processing
ADP
$97.1B
| $1.86M | 0.34% |
10,829
| – | – |
|
|
BNY
85
Bank of New York Mellon
BNY
$109B
| $1.85M | 0.34% |
36,839
| – | – |
|
86
CME Group
CME
$91.9B
| $1.8M | 0.33% |
8,853
| – | – |
|
87
Becton Dickinson
BDX
$42.1B
| $1.8M | 0.33% |
6,772
| – | – |
|
88
Edwards Lifesciences
EW
$48.3B
| $1.78M | 0.32% |
22,902
| – | – |
|
89
Chubb
CB
$137B
| $1.77M | 0.32% |
11,340
| – | – |
|
90
Norfolk Southern
NSC
$78.3B
| $1.74M | 0.32% |
8,979
| – | – |
|
91
Xcel Energy
XEL
$50.4B
| $1.74M | 0.32% |
27,170
| – | – |
|
92
HCA Healthcare
HCA
$83.5B
| $1.73M | 0.31% |
11,708
| – | – |
|
93
S&P Global
SPGI
$124B
| $1.68M | 0.3% |
6,137
| – | – |
|
94
CSX Corp
CSX
$98.1B
| $1.63M | 0.3% |
67,563
| – | – |
|
95
Trane Technologies
TT
$106B
| $1.57M | 0.29% |
11,828
| – | – |
|
96
Medtronic
MDT
$105B
| $1.57M | 0.28% |
13,749
| – | – |
|
97
Abbott
ABT
$175B
| $1.51M | 0.28% |
17,447
| – | – |
|
98
Illinois Tool Works
ITW
$79.7B
| $1.44M | 0.26% |
7,956
| – | – |
|
99
Colgate-Palmolive
CL
$72.1B
| $1.44M | 0.26% |
20,870
| – | – |
|
100
Bunge Global
BG
$23.7B
| $1.43M | 0.26% |
24,810
| – | – |
|
Similar funds
MWA
SFP
CA
MFS
ECM
NRG
HW
LAM
Kintegral Advisory's Q4 2019 Portfolio in Review
As of Q4 2019, Kintegral Advisory held 269 positions worth $550M, up 9.5% from $502M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 1.1%. Kintegral Advisory opened 1 new position and exited 2, leaving the 269-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
- Kintegral Advisory's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 17,299 shares worth $52K.
- Kintegral Advisory added most to Bristol-Myers Squibb in Q4 2019, an estimated $991K increase.
- Kintegral Advisory's biggest Q4 2019 reduction was 3M, cutting an estimated $560.
- Kintegral Advisory fully exited Celgene Corp in Q4 2019, selling an estimated $1.72M.
- Kintegral Advisory's ten largest holdings make up 29% of its $550M portfolio in Q4 2019.
- Kintegral Advisory opened 1 new position and closed 2 in Q4 2019.
- Kintegral Advisory's portfolio value rose 9.5% quarter-over-quarter to $550M.
Based on Kintegral Advisory's 13F filing for Q4 2019, filed 10 Feb 2020.